Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
An article from
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
Published Aug. 27, 2026
AstraZeneca office in San Francisco, Calif., on Nov. 15, 2020.
Alamy
AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease - Amgen (NASDAQ:AMGN), AstraZenec
Amgen, AZ’s Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
Medicamento da AstraZeneca e da Amgen para asma tem sucesso em estudo avançado
Medicamento da AstraZeneca reduz inflamação crônica no esôfago, mostra estudo
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data
